Invention Grant
- Patent Title: Nicotinic receptor antagonists and pioglitazone as therapeutic agents for Covid-19
-
Application No.: US17446021Application Date: 2021-08-26
-
Publication No.: US11766429B1Publication Date: 2023-09-26
- Inventor: Paul Ronald Sanberg , Christian Bernard Brechot , Shyam S. Mohapatra , Subhra Mohapatra
- Applicant: University of South Florida
- Applicant Address: US FL Tampa
- Assignee: University of South Florida
- Current Assignee: University of South Florida
- Current Assignee Address: US FL Tampa
- Agency: Smith & Hopen, P.A.
- Agent Michele L. Lawson
- Main IPC: A61K31/4439
- IPC: A61K31/4439 ; A61P31/14 ; A61K31/13
Abstract:
A method of treating severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), otherwise known as COVID-19, infection by administering nicotinic receptor antagonists and/or PPAR-γ agonists is presented. A combination of mecamylamine, or an isomer thereof, and pioglitazone synergistically reduces replication of SARS-CoV-2 in virus-infected cells and also synergistically reduces inflammatory cytokines such as IL-6, IL-β, and TNFα, which have been associated with SARS-CoV-2 infection.
Information query
IPC分类:
